1. Vanover KE, Davis RE, Zhou Y, et al. Dopamine D2 receptor occupancy of lumateperone (ITI-007): a positron emission tomography study in patients with schizophrenia. Neuropsychopharmacology. 2019;44(3):598–605.
2. Davis RE, Vanover KE, Zhou Y, et al. ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers. Psychopharmacology (Berl). 2015;232(15):2863–72.
3. Intra-Cellular Therapies. Intra-Cellular Therapies receives FDA fast track designation for lumateperone for the treatment of schizophrenia [media release]. 20 Nov 2017. http://www.intracellulartherapies.com.
4. Intra-Cellular Therapies. FDA approves Intra-Cellular Therapies’ novel antipsychotic, CAPLYTA® (lumateperone) for the treatment of schizophrenia in adults [media release]. 23 Dec 2019. http://www.intracellulartherapies.com.
5. Intra-Cellular Therapies. Caplyta (lumateperone) capsules, for oral use: US prescribing information. 2019. http://www.accessdata.fda.gov/. Accessed 31 Jan 2020.